File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1177/0310057X0903700212
- Scopus: eid_2-s2.0-65549137588
- PMID: 19400494
- WOS: WOS:000265276300016
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Outcome of patients receiving high dose vasopressor therapy: A retrospective cohort study
Title | Outcome of patients receiving high dose vasopressor therapy: A retrospective cohort study |
---|---|
Authors | |
Keywords | Critical care Critical illness Mortality Shock Vasoconstrictor agents |
Issue Date | 2009 |
Publisher | Australian Society of Anaesthetists. The Journal's web site is located at http://www.aaic.net.au |
Citation | Anaesthesia And Intensive Care, 2009, v. 37 n. 2, p. 286-289 How to Cite? |
Abstract | The aim of this study was to determine the hospital survival of patients receiving high doses of catecholamines. A retrospective observational study was conducted in a 22-bed multidisciplinary adult intensive care unit of a tertiary referral university hospital. All patients (n=64) receiving >100 μg/min of adrenaline or noradrenaline or adrenaline and noradrenaline combined over a one-year period were studied to determine survival to intensive care unit and hospital discharge. Four patients survived to intensive care unit discharge and hospital discharge (6.25%, 95% CI 0.3 to 12.2%). Survival was 3.3% (95% CI 0 to 7.9%) in the subgroup of 60 patients who received >100 μg/min noradrenaline and 3.6% (95% CI 0 to 8.6%) in the 55 patients who received >2 μg/kg/min noradrenaline. None of the 32 patients who received >200 μg/min noradrenaline survived. We conclude that the survival of patients requiring high doses of catecholamines is poor, but the use of such doses is probably not futile. It remains for individual clinicians, patients and their surrogates to decide whether use of high doses of vasopressor is appropriate, given the low probability of survival. |
Persistent Identifier | http://hdl.handle.net/10722/145446 |
ISSN | 2023 Impact Factor: 1.1 2023 SCImago Journal Rankings: 0.534 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jenkins, CR | en_HK |
dc.contributor.author | Gomersall, CD | en_HK |
dc.contributor.author | Leung, P | en_HK |
dc.contributor.author | Joynt, GM | en_HK |
dc.date.accessioned | 2012-02-23T12:10:20Z | - |
dc.date.available | 2012-02-23T12:10:20Z | - |
dc.date.issued | 2009 | en_HK |
dc.identifier.citation | Anaesthesia And Intensive Care, 2009, v. 37 n. 2, p. 286-289 | en_HK |
dc.identifier.issn | 0310-057X | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/145446 | - |
dc.description.abstract | The aim of this study was to determine the hospital survival of patients receiving high doses of catecholamines. A retrospective observational study was conducted in a 22-bed multidisciplinary adult intensive care unit of a tertiary referral university hospital. All patients (n=64) receiving >100 μg/min of adrenaline or noradrenaline or adrenaline and noradrenaline combined over a one-year period were studied to determine survival to intensive care unit and hospital discharge. Four patients survived to intensive care unit discharge and hospital discharge (6.25%, 95% CI 0.3 to 12.2%). Survival was 3.3% (95% CI 0 to 7.9%) in the subgroup of 60 patients who received >100 μg/min noradrenaline and 3.6% (95% CI 0 to 8.6%) in the 55 patients who received >2 μg/kg/min noradrenaline. None of the 32 patients who received >200 μg/min noradrenaline survived. We conclude that the survival of patients requiring high doses of catecholamines is poor, but the use of such doses is probably not futile. It remains for individual clinicians, patients and their surrogates to decide whether use of high doses of vasopressor is appropriate, given the low probability of survival. | en_HK |
dc.language | eng | en_US |
dc.publisher | Australian Society of Anaesthetists. The Journal's web site is located at http://www.aaic.net.au | en_HK |
dc.relation.ispartof | Anaesthesia and Intensive Care | en_HK |
dc.subject | Critical care | - |
dc.subject | Critical illness | - |
dc.subject | Mortality | - |
dc.subject | Shock | - |
dc.subject | Vasoconstrictor agents | - |
dc.subject.mesh | APACHE | en_HK |
dc.subject.mesh | Aged | en_HK |
dc.subject.mesh | Cohort Studies | en_HK |
dc.subject.mesh | Epinephrine - therapeutic use | en_HK |
dc.subject.mesh | Female | en_HK |
dc.subject.mesh | Hospital Mortality | en_HK |
dc.subject.mesh | Humans | en_HK |
dc.subject.mesh | Intensive Care Units | en_HK |
dc.subject.mesh | Male | en_HK |
dc.subject.mesh | Middle Aged | en_HK |
dc.subject.mesh | Multiple Organ Failure - mortality | en_HK |
dc.subject.mesh | Norepinephrine - therapeutic use | en_HK |
dc.subject.mesh | Retrospective Studies | en_HK |
dc.subject.mesh | Vasoconstrictor Agents - therapeutic use | en_HK |
dc.title | Outcome of patients receiving high dose vasopressor therapy: A retrospective cohort study | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Jenkins, CR:cjenkins@hkucc.hku.hk | en_HK |
dc.identifier.authority | Jenkins, CR=rp01583 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1177/0310057X0903700212 | - |
dc.identifier.pmid | 19400494 | en_HK |
dc.identifier.scopus | eid_2-s2.0-65549137588 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-65549137588&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 37 | en_HK |
dc.identifier.issue | 2 | en_HK |
dc.identifier.spage | 286 | en_HK |
dc.identifier.epage | 289 | en_HK |
dc.identifier.isi | WOS:000265276300016 | - |
dc.publisher.place | Australia | en_HK |
dc.identifier.issnl | 0310-057X | - |